The mitogen activated protein (MAP) kinases or extracellular signal-regulated kinases (Erks) are activated in response to Ras expression or exposure to tumor promoters or to growth factors, and have been implicated in AP-1 transactivation in some models. We have shown that tumor promoter induced activation of the transcription factor AP-1 is required for induced neoplastic transformation in the Balb/C JB6 cell model. Jun and Fos family protein levels have been found not to be limiting for AP-1 response. The present study asks whether activation of Erks1 and 2 is required for AP-1 transactivation and transformation of JB6 cells and whether Erks might be targeted for cancer prevention. Expression of either of two dierent dominant negative kinase inactive Erk2 mutants in transformation sensitive (P+) JB6 cells substantially inhibited the tumor promoter induced activation of Erks1 and 2 and of AP-1 measured by a collagenase-luciferase reporter. Multiple mutant Erk2 expressing clonal lines were also rendered non-responsive to induced neoplastic transformation. These observations, together with our recent ®nding attributing AP-1 non-responsiveness to Erk de®ciency in a clonal line of transformation resistant (P7) cells, argue for a requirement for Erks1 and/or 2 activation in AP-1 transactivation in the mouse JB6 neoplastic progression model, and suggest the utility of Erks as a prevention target.
Introduction
The mitogen activated protein (MAP) kinases or extracellular signal-regulated kinases (Erks) are activated in response to Ras expression, exposure to tumor promoters or serum growth factors (Winston et al., 1995; Thomas, 1992; Cobb et al., 1991; Marshall, 1994) . Erks have been shown to catalyze in vitro phosphorylation of substrates involved in growth factor-stimulated gene regulation, including c-Jun and fos gene family members Fra-1 and Fra-2 and ets family members Elk-1 and Erg (Pulverer et al., 1991; Marais et al., 1993; Gruda et al., 1994; Buttice et al., 1996) . A role for the Erk family of protein serine/ threonine kinases in cell signaling in the Balb/C mouse JB6 model was ®rst suggested by the observation that Erk family members were coimmunoprecipitated with Jun and Fos family members (Berstine et al., 1994) . Neoplastic transformation by tumor promoters such as 12-O-tetradecanoylphorbol-13-acetate (TPA) and epidermal growth factor (EGF) is accompanied by induced c-Jun and AP-1 transactivation in JB6 promotion sensitive (P+) cells but not in resistant (P7) cells (Bernstein et al., 1989) . AP-1 activation appears to be required for transformation by TPA or EGF in P+ cells because speci®cally blocking transactivation using dominant negative c-Jun or AP-1 transrepressing retinoids blocks induced AP-1 activation and transformation (Dong et al., 1994; Li et al., 1996) . Although P7 cells are non-responsive for c-jun induction, c-Jun is not the factor limiting AP-1 transactivation in these cells. Overexpressing c-Jun in P7 cells did not convert these cells to the AP-1 responsive or transformation responsive P+ phenotype (Watts et al., 1995) , suggesting another limiting molecule in the signal transduction pathway. Recently, we have reported that promotion resistance in a clonal line of JB6 P7 cells is attributable to a de®ciency in basal and TPA-inducible Erk1 and/or 2 activity (Huang et al., 1998) .
Expression in rat ®broblasts of kinase inactive Erk1 and Erk2 mutants inhibited AP-1 transactivation induced by Ha-Ras, serum or phorbol ester (Frost et al., 1994) . Here, we hypothesize that Erk1 and Erk2 kinase activation is required for the TPA-and EGFinduced AP-1 activation and neoplastic transformation responses of the JB6 promotion sensitive (P+) cells. In the present studies, stable expression of dominant negative Erk2 in P+ cells inhibited tumor promoter induced phosphorylation of wild type Erk1 and Erk2, AP-1 transactivation, and neoplastic transformation. These results indicate that activation of Erk1 and/or Erk2 is required for tumor promoter induced transactivation of AP-1 and neoplastic transformation in the JB6 progression model and suggest the utility of Erks as a prevention target.
Results
Transient Y185F Erk2 expression inhibits AP-1 transactivation in JB6 P+ cells JB6 P+ cells were transiently transfected with the point mutant Y185F Erk2 expression construct. This mutation abrogates the putative activating phosphorylation site on Erk2 (Robbins et al., 1993) . TPA induced AP-1 dependent transcription by approximately threefold in P+ cells transfected with the reporter construct alone. Transient co-transfection with Y185F Erk2 inhibited TPA inducible AP-1 dependent transactivation in a dose responsive manner (Figure 1 ) with greater than 90% inhibition of AP-1 transactivation achieved by a 5 : 1 ratio of inhibitor to reporter.
Expression of dominant negative mutant Erk2 inhibits activation of Erks
Stable clonal transfectants of Y185F Erk2 were generated and expression of the Y185F mutant Erk2 was con®rmed by RT ± PCR using vector-speci®c primers. Y185F-5, Y185F-7 and Y185F-8 transfectants but not the P+/Neo controls expressed a PCR fragment which included the 5' histidine tag present in the Y185F Erk2 transcript (data not shown). We then examined the eects of mutant Y185F Erk2 expression on TPA-induced phosphorylated (activated) forms of Erk1/Erk2 (Figure 2a ). Basal levels of phospho-Erk were reduced in all three Y185F Erk2 transfectants compared to phospho-Erk in parental P+/Neo5 cells. Phospho-speci®c MAPK antibody detected substantial TPA-inducible phosphorylated Erk1 and Erk2 in P+/ Neo5 cells (Figure 2a ). In contrast, TPA induced little or no phosphorylated Erk proteins in the P+/Y185F-7 clone and substantially reduced TPA induced phosphoErk2 in the Y185F-5 and Y185F-8 Erk2 clonal transfectants.
To assess the activity of an independent mutant Erk2 on AP-1 dependent transactivation in P+ cells we generated stable transfectants of K52R mutant Erk2. While this point mutation impairs the catalytic eciency of Erk2, expression of the K52R also blocks phosphorylation of endogenous Erk1 and 2 (Robinson et al., 1996) . P+ cells expressing the K52R mutant Erk2 were mass selected, rather than clonally selected, and were stably cotransfected with the AP-1-Luciferase reporter plasmid. Figure 2b shows greatly reduced levels of Phospho-Erk1 and Erk2 after TPA or EGF exposure compared to the P+/AP-1 reporter-only cells.
Mutant Erk2 expression inhibits AP-1 transactivation in JB6 P+ cells
Fold induction of AP-1 activity was 3 ± 3.5 following 24 h TPA or EGF exposure in P+/AP-1 controls but absent in the P+/AP-1/K52R transfectants (Figure 3) . Similarly the Y185F clonal transfectants showed greatly reduced AP-1 activation in response to tumor promoter when compared to P+/Neo controls. It is noteworthy that the P+/Y185F-7 clonal line, which showed little or no Erk activation ( Figure 2a ) also showed no induced AP-1 transactivation (Figure 3) . Inhibition of tumor promoter-induced transactivation of AP-1 in the P+/AP-1/K52R transfectants was observed at 6, 12, 24 and 36 h after TPA or EGF treatment ( Figure 4 ). To address the possibility that the concentration of TPA or EGF used for tumor promoter-induced transactivation of AP-1 in P+ cells was suboptimal for the kinase de®cient K52R transfectants, we exposed these cells to increasing nontoxic concentrations of TPA or EGF (0.1 ng/ml to 100 ng/ml; 1.6610 710 M to 1.6610 77 M) and observed no induction of AP-1 mediated transactivation in the P+/AP-1/K52R transfectants (data not shown). The results shown in Figures 3 and 4 utilized the collagenase-luciferase reporter (773 to +63) (Dong et al., 1994) . Similar inhibition of TPA induced AP-1 transactivation in the Y185F expressing P+ cells was seen when the reporters contained stromelysin promoter (7750 to +1) (Dong et al., 1994) or a 46AP-1 construct (data not shown). The observed inhibition of Erk and AP-1 activation occurred without signi®cant eects on cellular growth, as Y185F expressing clonal P+ cells showed growth rates similar to those of parental cells (data not shown). /AP-1/K52R cells were seeded into each well of 6-well plates. After culture at 378C for 24 h, the cells were starved for 48 h by replacing medium with 0.1% FBS MEM. Two to four hours after a medium change the cells were treated with TPA (10 ng/ml), EGF (10 ng/ml) or 0.1% DMSO (control) in 0.1% FBS for 30 min. The cells were extracted and phosphorylated Erk1 and Erk2 proteins were detected by Western analysis as described in the phosphoPlus MAPK antibody kit by New England Biolabs Expression of either Y185F or K52R Erk2 inhibits the transformation response in JB6 P+ cells P+Y185F and P+/AP-1/K52R transfectants were compared with the control neo-only and P+/AP-1 transfectant cells for their ability to show anchorageindependent transformation in response to tumor promoters. As seen in Figure 5 , none of the clonal P+/Y185F or mass selected P+/AP-1/K52R transfectants underwent signi®cant transformation in response to TPA or EGF in anchorage independent transformation assays. TPA or EGF-induced colony formation ranged from 1000 ± 2000/10 4 cells in the P+/AP-1 and P+/Neo-only transfectants whereas the tumor promoter treated P+/AP-1/K52R and P+/Y185F transfectants displayed a mean number of 90 colonies/10 4 cells and 120 colonies/10 4 cells, respectively.
Discussion
We showed previously that induced AP-1 appears necessary for the transformation response to tumor promoters in P+ cells (Dong et al., 1994; Li et al., 1996) and that stably blocking induced AP-1 causes the conversion of transformation sensitive P+ cells to the resistant P7 phenotype. Here we addressed the questions of whether Erks are required for the tumor promoter-induced AP-1 activation and transformation response in P+ cells and whether Erks might be targeted for prevention of carcinogenesis. We found that speci®cally blocking Erk1 and 2 activity by expressing kinase de®cient Erk2 in JB6 P+ cells inhibited tumor promoter-induced activation of AP-1 mediated transactivation and neoplastic transformation. This suggests that phosphorylation catalyzed by Erk2 is necessary for tumor promoter-induced transcriptional activation of promotion relevant genes. Since induced AP-1 is necessary for the tumor promoter-induced transformation response, Erk might serve as a molecular target for the prevention of carcinogenesis. Expression of kinase de®cient Erk2 in JB6 P+ cells was relatively non-toxic. Growth rates for parental P+ cells, Neo-only transfectant cells and Y185F Erk2 transfectant cells were similar. The conclusion that Erk2 activation appears to be required for AP-1 dependent transactivation of gene expression in JB6 P+ cells is supported by the following lines of evidence. Two Erk2 inhibitors that are both potent and speci®c for kinase activity also block AP-1 activity. The K52R and Y185F Erk2 kinase-de®cient mutants have similar properties and bind substrates with the same Figure 3 Stable expression of dominant negative Erk2 inhibits TPA/EGF induced AP-1 activation. 8610 3 JB6 P + /AP-1 or P + / AP-1/K52R cells were seeded into each well of 96-well plates, cultured overnight and then starved for 24 h by replacing medium with 0.1% FBS MEM. 2610 4 JB6 P+/Neo5, P+/Y185F-5, P+/ Y185F-7 and P+/Y185F-8 cells seeded in 24-well dishes were transiently transfected with 1 mg AP-1-luciferase vector (and 0.5 mg of b-gal vector). After 6 h these cells were allowed to recover in 4% FBS-MEM for 12 h and then starved in 0.1% FBS MEM for 12 h. The cells were treated with TPA (10 ng/ml) or EGF (10 ng/ml) for 18 h, then assayed for AP-1 activity. Results are expressed as fold-activation relative to DMSO solvent controls 4 of P+/AP-1, P-/AP-1, P+/ AP1/K52R, P+/Neo5, P+/Y185F-5, P+/Y185F-7 and P+/ Y185F-8 were treated with TPA (10 ng/ml) or EGF (10 ng/ml) in 1 ml of 0.33% BME agar containing 10% FCS laid over 3.5 ml of 0.5% BME agar containing 10% FBS in each well of a 6-well plate or 1.5 ml of 0.33% agar over 7.0 ml 0.5% agar of a 60 mmdiameter dish. The cultures were maintained in a 378C, 5% CO 2 incubator for 14 ± 16 days, and the anchorage independent colonies were scored speci®city as endogenous Erk2 (Robbins et al., 1993) . Kinase de®cient Erk2 blocked TPA-induced AP-1-dependent transactivation using three dierent AP-1 promoter-reporter constructs. Independent confirmation has come from our Erk2 reconstitution experiments in which a promotion resistant clonal line of JB6 cells expressing wild type Erk2 gained tumor promoter inducibility of AP-1 dependent transactivation and neoplastic transformation response (Huang et al., 1998) . Some of the alternative candidates for targets of mutant Erk can be excluded. Although evidence points to C-Jun-N-Terminal Kinase (JNK) as the tumor promoter-induced kinase responsible for Jun activation, JNK is not a substrate of Erk2, nor does it bind to kinase de®cient Erk2 (Minden et al., 1994) . In fact, using kinase de®cient Erk, activated Ras, a chimeric Gal4-Jun expression vector and the 5xGal4-luc reporter construct, Westwick et al. (1994) showed that activation of c-Jun and JNK occurs independently of Erks. It is unclear at the present time whether targeting Erk1, Erk2 or both is responsible for inhibiting AP-1 transactivation. Frost et al. reported that only the combination of kinase de®cient Erk1 along with kinase de®cient Erk2 blocked TPA induced AP-1 activity in REF-52 cells (Frost et al., 1994) . It is also unknown whether the Erk targeting is direct or indirect.
Although the two kinase de®cient Erk2 mutants are rendered functionally inactive by distinct physiological means, both inhibit phosphorylation of downstream substrates (Robbins et al., 1993) . The mechanism by which the K52R and Y185F Erk2 mutants inhibit EGF and TPA-induced AP-1 activity and anchorage independent growth in JB6 P+ cells is not known. One proposed mechanism is that the kinase de®cient Erk2 prevents endogenous Erks from phosphorylating nuclear substrates. Erks have many substrates including other protein kinases (Sturgill et al., 1988; Gregory et al., 1989; Ahn et al., 1990; Lee et al., 1992; Waskiewicz et al., 1997) membrane receptors, Takashima et al., 1991) and nuclear proteins involved in transcriptional control (Waskiewicz et al., 1997; Northwood et al., 1991; Takashima et al., 1991; Alvarez et al., 1991; . The kinase de®cient Erk2 mutant protein may function by decreasing phosphorylation of Erk substrates such as Elk-1, thereby inhibiting Elk-1 mediated ternary complex formation (TCF) . Elk-1 is an Ets domain protein that binds DNA, mediates ternary complex formation and contains MAP kinase phosphorylation sites (Dalton et al., 1992) as well as JNK sites (Cavigelli et al., 1995; Whitmarsh et al., 1995; Zinck et al., 1995) . TCF modi®cation by Erk1 and Erk2 appears to be required for TCF activity and binding to the serum response factor (SRF) which then binds to the serum response element (SRE) of cfos promoter (Triesman, 1992; Shaw et al., 1989) , although there may be exceptions (Miranti et al., 1995) . The SRE is a regulatory sequence required for growth factor-induced transient transcriptional activation of c-fos. cFos is a member of the AP-1 complex which is a dynamic DNA binding protein dimer composed of the protein products of jun and fos family protooncogenes (Curran et al., 1988; Vogt et al., 1990; Angel et al., 1991) . Another ternary complex factor, SAP1a, is also phosphorylated by Erk but not JNK in NIH3T3 cells in response to mitogenic but not stress stimuli (Strahl et al., 1996) . Angel et al. (1988) , Kortenjann et al. (1994) and Westwick et al. (1994) have shown that dominant negative Erks inhibit c-fos promoter activation by various stimuli. Our previous observations (Ben-Ari et al., 1992) exclude c-fos transcription as a factor limiting AP-1 transactivation in JB6 P-cells. In these studies, c-fos mRNA was TPA inducible in both P+ and P7 cells with somewhat greater induction seen in P7 cells. This observation was made in independent variants of P+ and P7 cells, including a P7 clone that is Erk de®cient. (Ben-Ari et al., 1992; Bernstein et al., 1991 and M Young, unpublished) . In addition the P+/Y185F cells showed little or no inhibition of c-fos transcriptional activation (M Young, and R Watts, unpublished) . The kinase de®cient Erk2 may thus inhibit AP-1 activation by operating on a pathway that is independent of c-fos transcription. Other candidate pathways may involve activating protein-protein interactions between Erk substrates and Fos or Jun family proteins. In vitro interactions have been demonstrated between Jun/Fos and an Ets-family protein, Erg (Buttice et al., 1996) . Clearly, an understanding of Erk dependent events required for AP-1 transactivation will require further investigation.
Materials and methods

Plasmids and reagents
AP-1 luciferase reporter plasmid (Col-Luc), CMV-neo vector plasmid, and SV2-neo vector plasmid were previously described (Li et al., 1996) . Two CMV promoter driven mutant Erk2 expression constructs, Y185F and K52R were generous gifts from Dr Melanie Cobb (Frost et al., 1994) . Fetal bovine serum (FBS) was from Gibco; Lipofectin and LipofectAMINE were from GIBCO ± BRL; Eagles' minimal essential medium (MEM) and TPA were from Calbiochem; EGF was from Collaborative Research; luciferase assay substrate was from Promega; and PhosphoPlus MAPK antibody kit was from New England Biolabs.
Cell culture
JB6 promotion sensitive (P+) C141 cell lines and its transfectants and promotion resistant (P7) C130.7b cell lines (Colburn et al., 1981) were cultured in monolayer at 378C, 5% CO 2 using Eagle's minimal essential medium containing 5% fetal calf serum, 2 mM L-glutamine, and 25 mg of gentamicin per ml.
Generation of stable Y185F and K52R transfectants
JB6 P+ cells were cotransfected with Y185F mutant Erk2 (5 mg) and SV2-neo (0.5 mg) using Lipofectin reagent for 5 h. Transfected cells underwent selection for antibiotic resistance to G418 (400 mg/ml) for 2 ± 2.5 weeks in MEM with 5% FBS. Clonal Y185F mutant Erk2 transfectants were generated by clonal expansion of G418-resistant colonies isolated by ring-cloning. The clonal cell lines derived from transfection of the Y185F mutant Erk2 into P+ cells are hereafter referred to as P+/Y185F-5, Y185F-7, and Y185F-8. The neo-only control is referred to as P+/Neo-5. To generate K52R transfectants, JB6 P+ cells in 6-well plates were transfected with 2 mg of AP-1 luciferase reporter plasmid and 0.3 mg of CMV-neo vector with or without 12 mg mutant Erk2 K52R plasmid using LipofectAMINE reagent. After selection, stable transfectants expressing Erk K52R and AP-1 reporter or AP-1 reporter only were pooled and maintained in G418-free MEM.
Assay of AP-1 transcriptional activity P+/AP-1 and P+/AP-1/K52R transfectants were trypsinized and 8610 3 viable cells were suspended in 100 ml 5% FBS MEM medium and added to each well of a 96-well plate. Twelve to twenty-four hours later, cells were starved by culturing cells in 0.1% FBS MEM beginning at 12 h prior to exposure to EGF (10 ng/ml) or TPA (20 ng/ml) for 24 h at 378C and 5% CO 2 . The cells were extracted with lysis buer and luciferase activity was measured using a luminometer (Monolight 2010). P+, P7 and clonal P+/ Y185F cell lines were transiently transfected with AP-1-luciferase reporter and assayed as described in the legend to Figure 1 .
Anchorage-independent transformation assay
1610
4 P+ cells or transfectant cells were exposed to (a) TPA (0, 20, or 100 ng/ml) or EGF (10 ng/nl) in 1 ml of 0.33% BME agar containing 10% FBS layered over 3.5 ml of 0.5% BME agar containing 10% FBS or (b) 0 or 20 ng/ ml TPA or 10 ng/ml EGF in a 60-mm dish. The cultures were maintained in a 378C, 5% CO 2 incubator for 14 ± 16 days and the anchorage independent colonies were scored by the methods described (Dong et al., 1994; Colburn et al., 1981) .
Analysis of MAP kinase Erk1, 2 activation
Immunoblotting for phosphorylated Erk1 and Erk2 proteins was carried out as described in the PhosphoPlus MAPK antibody kit by New England Biolabs, using antibodies against Erk1 and Erk2 (p44 and p42) and phospho-speci®c MAPK antibodies against phosphorylated tyrosine 204 of p44 and p42 MAPKs. Both Y185F and K52R/AP-1 transfectant cells were seeded at 8610 4 cells per well in 6 well dishes for 24 h in 5% serum. The transfectant cells were serum starved by exchanging the media with 0.1% serum for 48 h and then treated with 0.1% DMSO solvent or 10 or 20 ng/ml TPA (1.6610 78 M) in 1 ml 0.1% serum containing media for 30 min. The cells were washed and lysed with 100 ml lysis buer and cellular lysates were analysed by Western blotting. Thirty-®ve ml of cellular lysates were separated on an 8% polyacrylamide gel, transferred to PVDF membrane and blotted with rabbit anti phospho-Erk (NEB). The antibody complexes were detected with antirabbit HRP and visualized by ECL (Amersham).
Abbreviations AP-1, activator protein-1; EGF, epidermal growth factor; Erk, extracellular signal-regulated protein kinase; MAP kinase, mitogen-activated protein kinase; JNK, c-Jun Nterminal kinase; TPA, 12-O-tetradecanoyl phorbol-13-acetate; UV, ultraviolet.
